Acumen Posts Q3 GAAP Loss Per Share 2 Cents Below Estimate
Photo: TokenPost
Acumen Pharmaceuticals expects its $78.6 million balance to support clinical and operating activities into early 2027 after posting a third-quarter GAAP loss of 35 cents per share, 2 cents narrower than estimated. The balance included cash, cash equivalents and marketable securities as of Sept. 30, 2026. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
